Biodexa Provides Update On Progression Free, Overall Survival In Phase 1 Study Of MTX110 In Recurrent Glioblastoma
Biodexa Provides Update On Progression Free, Overall Survival In Phase 1 Study Of MTX110 In Recurrent Glioblastoma
MAGIC-G1 is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery (CED) via implanted refillable pump and catheter. Patients received MTX110 via intermittent repeated CED infusions. As of today, the status of patients in Cohort A is as follows:
MAGIC-G1是一项开放标签，剂量递增研究，旨在评估经过植入式可供补充的泵和导管通过传导增强输送（CED）间歇性输入MTX110的可行性和安全性。患者通过间歇性重复的CED输注接受了MTX110。截至今天，A组患者的状况如下：
Patients #1 and #2 have deceased with overall survival (OS) since start of treatment of 12 months and 13 months, respectively.
患者#1和#2在开始治疗后分别存活12个月和13个月，已经去世。
Patients #3 and #4 remain in post-study follow-up. Patient #3 had progression free survival (PFS) of six months and OS thus far of 13 months since start of treatment. Patient #4 has not yet had confirmed progression and, as of today, has PFS and OS of 12 months since start of treatment.
患者#3和#4仍在研究后随访中。从治疗开始至今，患者#3的无进展生存（PFS）为六个月，迄今为止的总生存（OS）为13个月。患者#4尚未确认疾病进展，截至今日，治疗开始后患者#4的PFS和OS分别为12个月。
